Atai Beckley N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments, has announced the successful completion of the strategic combination between atai Life Sciences and Beckley Psytech Limited in an all-share transaction. The combined company brings together world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health.
Latham & Watkins LLP represented atai Life Sciences in the transaction with a corporate team led by New York partner Nathan Ajiashvili, London partner Robbie McLaren, and Orange County partners Scott Shean and Brian Umanoff, with associates Samantha Peacock, Abby Timmons, Richard Dodding, Kaj Nielsen, Christopher Siino, Adam Picker, Elana Cates, and Chloe Barr. Advice was also provided on executive compensation and employee benefits matters by London partner Sarah Gadd, Washington, D.C. partner David Della Rocca, with associate Venice Ma; and on public company matters by New York counsel Irina Yevmenenko, with associate Catriela Cohen.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
